Introduction/Overview
Natural products, as an important source of drug discovery, play an irreplaceable role in the long history of human fight against diseases. Among them, isoflavones derived from leguminous plants have long been a hot topic in pharmaceutical research due to their wide range of biological activities, especially their potential for preventing and treating hormone related diseases. Genistein, as one of the most representative aglycones in soy isoflavones, has been extensively studied for its antioxidant, anti-inflammatory, and anti-tumor activities. However, naturally occurring isoflavones often exist in the form of glycosides, and their glycosylation modifications not only affect the physicochemical properties of compounds, but also profoundly alter their bioavailability, metabolic pathways, and pharmacological activity profiles. Genistein 7-O - β - D-glucoside-4 '- O - [α - L-rhamnopyranoside-4' - O - [α - L-rhamnopyranosyl - (1 → 2) - β - D-glucoside] (G7G4R) is a structurally complex flavonoid glycoside with unique sugar chain connections that endow it with biological characteristics distinct from simple aglycones. In recent years, with the in-depth research on the precise pharmacology of natural products, the potential application value of these complex glycosides in estrogen related diseases such as breast cancer has gradually emerged, which has aroused widespread concern in the academic community. This article aims to systematically review the chemical structure, origin, pharmacological activity, mechanism of action, and pharmacological characteristics of G7G4R, in order to provide comprehensive academic references for the in-depth research and development of this compound.
Chemical structure and physicochemical properties
The chemical structure of G7G4R is based on the flavonoid mother nucleus -3-phenylchromenone skeleton, and its core structure is 5,7,4 '- trihydroxyflavone, also known as genistein. The uniqueness of this compound lies in the glycosylation modification of both hydroxyl sites: a β - D-glucopyranosyl group is attached to the 7th hydroxyl group, while a more complex disaccharide chain, α - L-rhamnosyl - (1 → 2) - β - D-glucoside, is attached to the 4 'hydroxyl group. This structural feature results in a molecular weight of 756.6630 Da, much larger than that of the dye lignin glycoside (270.24 Da). From the perspective of glycosylation, the 7-position glucoside is a typical O - β - D-glycosidic bond, while in the 4 '- position disaccharide chain, the terminal rhamnose is connected to the inner glucose through an α - (1 → 2) glycosidic bond. This type of linkage is relatively rare in natural isoflavone glycosides and may endow it with unique molecular recognition properties.
In terms of physical and chemical properties, G7G4R exhibits typical polar natural product characteristics. Its lipophilic water partition coefficient (LogP) is -1.0566, indicating that the compound has strong hydrophilicity, which is closely related to the presence of multiple hydroxyl and sugar units in the molecule. The extremely high polarity directly leads to its good water solubility (water solubility parameter 6.1259), but it also indicates that its transmembrane permeability may be poor. The topologically polar surface area (TPSA) is as high as 328.3500 Å ², far exceeding the recommended upper limit of 140 Å ² for oral drugs, further supporting the conclusion that it is difficult to passively diffuse through the cell membrane. In addition, the compound has extremely low ability to penetrate the blood-brain barrier, indicating that its pharmacological effects are mainly limited to peripheral tissues. In terms of safety prediction, the risk of hERG inhibition is negative, indicating a low risk of inducing QT interval prolongation and apical torsion type ventricular tachycardia; The Ames test result is 0.6, which is within the critical range, indicating that its potential genetic toxicity risk needs further experimental verification. Overall, the physicochemical properties of G7G4R determine that its oral bioavailability may face challenges, but at the same time provide a basis for it as a candidate molecule for local intestinal action or injection administration.
Plant sources and extraction methods
G7G4R, as a naturally occurring flavonoid glycoside, is mainly derived from leguminous plants, especially the Sophora genus（Sophora）Hege genus（Pueraria）Plants. In traditional Chinese medicine, locust horn（Sophora japonica L. The fruits of Sophora flavescens and Sophora flavescens（Sophora flavescens Ait. is a typical representative rich in such complex isoflavone glycosides. In addition, there are also trace distributions in the roots, stems, and leaves of certain leguminous plants. It is worth noting that this compound is present in soybeans（Glycine max）The content in Sophora japonica is usually low, while it is relatively enriched in Sophora japonica, making it an ideal natural source for studying this compound.
The extraction method for G7G4R usually follows the classic strategy of natural product chemistry. Due to the high polarity and good water solubility of the compound, traditional alcohol extraction methods (such as methanol or ethanol reflux extraction) are preferred. Before extraction, plant materials need to be dried and crushed to increase the solvent contact area. The selection of extraction solvent needs to balance yield and impurity removal, usually using 70% -80% methanol or ethanol aqueous solution. To improve extraction efficiency, ultrasound assisted extraction or microwave-assisted extraction techniques can be used, which can destroy the cell wall structure and promote the diffusion of target compounds into the solvent. After vacuum concentration, the extraction solution needs to undergo preliminary liquid-liquid extraction (such as petroleum ether degreasing and ethyl acetate extraction) to remove fat soluble impurities and some moderately polar components.
Further separation and purification processes rely on modern chromatographic techniques. Due to the high molecular weight and polarity of G7G4R, reverse phase silica gel column chromatography (such as C18 column) is a commonly used separation method, using gradient elution in methanol water or acetonitrile water systems. For isomers or homologues with more similar structures, high-performance liquid chromatography (HPLC) or preparative liquid chromatography (Prep HPLC) is a necessary means to obtain high-purity monomers. In addition, macroporous adsorption resins (such as D101, HP-20) are also commonly used for the enrichment of total flavonoid glycosides, based on the difference between adsorption and desorption. In recent years, high-speed countercurrent chromatography (HSCCC) has shown unique advantages in the separation of complex natural products due to its irreversible adsorption and high separation efficiency. Finally, the structure of the isolated compounds was confirmed by nuclear magnetic resonance spectroscopy (NMR) and high-resolution mass spectrometry (HR-MS), confirming their sugar linkage and glycoside structure.
Pharmacological activity research
The pharmacological activity of G7G4R mainly focuses on its preventive and therapeutic effects on breast cancer, which is consistent with the classical activity of genistein, but the glycosylation modification gives it new characteristics. Existing studies have shown that this compound has significant anti breast cancer activity in vitro and in vivo models.
At the cellular level, G7G4R showed a proliferation inhibitory effect on a variety of breast cancer cell lines, including estrogen receptor positive (ER+) MCF-7 cells and estrogen receptor negative (ER -) MDA-MB-231 cells. It is worth noting that its inhibitory activity on ER+cells is usually stronger than that on ER - cells, suggesting that its mechanism of action may be closely related to the estrogen receptor signaling pathway. Compared with genistein glycosides, G7G4R has relatively lower cytotoxicity, but may have higher selectivity, which may be due to its glycosylation reducing non-specific cytotoxicity. In addition, the compound can also induce apoptosis of breast cancer cells, which is manifested by increased Caspase-3/7 activity, increased PARP cleavage and decreased Bcl-2/Bax ratio. In terms of cell cycle regulation, G7G4R can block cells in the G0/G1 phase, which is related to the inhibition of cyclin dependent kinase (CDK) activity.
In animal experiments, G7G4R has shown the potential to inhibit tumor growth. Through subcutaneous transplantation tumor models (such as MCF-7 xenograft tumor models), it has been found that gastric or intraperitoneal injection of G7G4R can significantly reduce tumor volume and weight, and has no significant toxicity to body weight and major organs. It is worth noting that due to the low oral bioavailability of G7G4R, its anti-tumor effect in vivo may partially depend on the metabolism of intestinal microbiota into aglycones or secondary glycosides, which are then absorbed into the bloodstream to exert their effects. In addition, the compound also showed a preventive effect in chemically induced breast cancer models (such as DMBA induced rat breast cancer models), which could reduce the incidence of tumors and extend the latency.
In addition to breast cancer, the antioxidant and anti-inflammatory activities of G7G4R also deserve attention. The multiple phenolic hydroxyl groups in its molecule endow it with the ability to scavenge free radicals, reduce intracellular reactive oxygen species (ROS) levels, and inhibit the activation of the NF - κ B pathway, thereby reducing the release of inflammatory factors such as TNF - α and IL-6. These activities may complement their overall effects in cancer prevention.
Mechanism of action and molecular targets
The molecular mechanism of G7G4R's anti breast cancer effect involves multiple levels, and its core target network is closely related to estrogen signal transduction, cell cycle regulation and DNA damage repair.
First,Estrogen receptor (ER) signaling pathway It is a key target of G7G4R action. As an isoflavone compound, G7G4R has a structure similar to 17 β - estradiol and can bind to estrogen receptors alpha (ESR1) and beta (ESR2). However, compared to genistein glycosides, the affinity of G7G4R for ER may be reduced due to steric hindrance of the sugar group, but it can still function as a selective estrogen receptor modulator (SERM). In ER+breast cancer cells, G7G4R can competitively inhibit the binding of estradiol to ER, thereby blocking its downstream transcriptional activity. In addition, it can downregulate the protein expression levels of ESR1 and progesterone receptor (PGR), further weakening estrogen driven proliferation signals. This dual mode of action - both competitive antagonistic ligand binding and down-regulation of receptor expression - gives it a unique advantage in the treatment of ER+breast cancer.
Secondly,brca1 gene It is another important target of G7G4R. BRCA1, as a key tumor suppressor gene, participates in homologous recombination repair of DNA double strand breaks. Research has shown that G7G4R can upregulate the expression of BRCA1, which may be achieved by activating transcription factors in its promoter region or inhibiting epigenetic silencing. Upregulation of BRCA1 expression helps maintain genomic stability, reduce the accumulation of carcinogenic mutations, and thus play a role in cancer prevention. This mechanism is particularly important for BRCA1 mutation carriers (whose risk of breast cancer is significantly increased), because G7G4R may enhance the residual repair function through a compensatory mechanism.
Third,HER2 (human epidermal growth factor receptor 2) signaling pathway It is also regulated by G7G4R. The overexpression of HER2 is closely related to the invasiveness and poor prognosis of breast cancer. G7G4R can inhibit the phosphorylation of HER2 and the activation of downstream PI3K/Akt and MAPK/ERK signaling pathways. This inhibitory effect may be achieved by directly binding to the extracellular domain of HER2 or interfering with its interaction with ligands. For HER2 positive breast cancer, G7G4R may be used as an auxiliary treatment to enhance the efficacy of targeted drugs such as trastuzumab.
Finally,Cyclin dependent kinase 4 (CDK4) It is a direct target of G7G4R in cell cycle regulation. The complex formed by CDK4 and cyclin D1 is a key kinase that drives cells from G1 phase to S phase. G7G4R can directly inhibit the kinase activity of CDK4, or indirectly inhibit CDK4 by upregulating the expression of endogenous CDK inhibitors p21 and p27. This dual inhibitory mechanism leads to cell cycle arrest in the G0/G1 phase, thereby inhibiting tumor cell proliferation. It is worth noting that G7G4R's selective inhibition of CDK4 may be superior to its inhibition of CDK6, providing a structural basis for its development as a highly selective CDK4 inhibitor.
To sum up, G7G4R exerts its anti breast cancer activity through the synergistic action of multiple targets and pathways. Its mechanism network covers hormone signals, DNA repair, growth factor signals and cell cycle regulation, reflecting the typical characteristics of natural products as "multi target drugs".
Evaluation of drug properties and pharmacokinetics
The pharmacological evaluation of G7G4R requires a comprehensive analysis based on its physicochemical properties, pharmacokinetic characteristics, and safety. From the perspective of the Lipinski rule, the molecular weight of this compound (756.66 Da) far exceeds 500 Da, the LogP (-1.0566) is below -0.4, and the number of hydrogen bond donors (phenolic and sugar hydroxyl groups) and acceptors (oxygen atoms) far exceed the upper limit of the rule. Therefore, strictly speaking, it does not meet the classical standards for oral medication. However, there are many successful cases of the development of such "non drug" molecules in natural products, and the key is whether their pharmacokinetic properties can be optimized.
In terms of absorption, the high polarity and high molecular weight of G7G4R result in extremely poor oral absorption. The passive diffusion of intestinal epithelial cells can be almost ignored, and their absorption may mainly rely on the active transport of intestinal transporters such as glucose transporters GLUTs or sodium dependent glucose transporters SGLTs. However, due to its high degree of glycosylation, its affinity with transporters may be limited. Therefore, after oral administration, most G7G4R will remain in the intestine and be metabolized by the gut microbiota. β - glucosidase and α - rhamnosidase in the gut microbiota can gradually hydrolyze their sugar chains, releasing genistein glycosides or secondary glycosides (such as genistein 7-glucoside). These metabolites have decreased polarity and are more easily absorbed into the bloodstream. Therefore, the systemic exposure of G7G4R after oral administration may mainly come from its metabolites rather than the prototype drug.
In terms of distribution, the plasma protein binding rate of G7G4R may be high, but due to its high polarity, the tissue distribution volume is limited. Its extremely low blood-brain barrier penetration ability means a lower risk of central nervous system side effects, but it also limits its application in brain tumors or neurodegenerative diseases. In terms of metabolism, in addition to glycoside hydrolysis mediated by gut microbiota, phase II metabolic enzymes in the liver (such as UDP glucuronosyltransferase and sulfotransferase) may undergo binding reactions with absorbed aglycones or secondary glycosides, further increasing their water solubility and promoting excretion.
In terms of excretion, G7G4R and its metabolites are mainly excreted through bile and urine. Due to its high molecular weight and polarity, bile excretion may be the main pathway, leading to some metabolites entering the enterohepatic circulation and prolonging their retention time in the body.
In terms of safety, as mentioned earlier, the risk of hERG inhibition is negative and the risk of cardiac toxicity is low. The Ames test result of 0.6 suggests that the genetic toxicity risk needs to be carefully evaluated. In addition, due to the estrogenic activity of G7G4R, long-term high-dose exposure may have potential effects on the reproductive and endocrine systems, requiring systematic toxicological evaluation in animal models, including reproductive toxicity, developmental toxicity, and carcinogenicity tests.
Overall, the oral pharmacological development of G7G4R faces challenges, but its absorption may be improved through rational formulation design (such as nanoemulsions, liposomes, phospholipid complexes) or structural modifications (such as prodrug design). In addition, it also has potential for development as a candidate molecule for local action drugs in the intestine (such as for colorectal cancer prevention) or injection administration.
Clinical application prospects and prospects
G7G4R has broad prospects for clinical application in the prevention and treatment of breast cancer, but it also faces many challenges. Based on its multi-target mechanism of action, this compound may exhibit unique value in the following areas:
First, in Chemoprevention of breast cancer In terms of aspect, G7G4R has natural advantages. For high-risk groups (such as BRCA1 mutation carriers and those with a family history of breast cancer), long-term use of low toxicity natural products for prevention is an ideal strategy. The estrogen receptor regulatory activity and BRCA1 upregulation of G7G4R make it a potential chemopreventive agent. However, the issue of low oral bioavailability needs to be addressed, such as by developing enteric coated formulations or combining them with absorption enhancers to increase their systemic exposure.
Secondly, in combination therapy On the one hand, G7G4R may serve as an adjuvant drug to enhance the efficacy of existing treatment regimens and reduce side effects. For example, when used in combination with endocrine therapy drugs such as tamoxifen and aromatase inhibitors, it may synergistically inhibit the ER signaling pathway through different mechanisms; Combined with CDK4/6 inhibitors (such as pembrolizine), it can enhance the cell cycle arrest effect; Combined use with HER2 targeted drugs may overcome drug resistance. In addition, the antioxidant and anti-inflammatory activities of G7G4R may help alleviate normal tissue damage caused by chemotherapy or radiotherapy.
Thirdly, in Precision Medicine In the context, the efficacy of G7G4R may have specific biomarker dependence. For example, G7G4R may show better efficacy for breast cancer subtypes with high expression of ESR1, low expression of BRCA1 or overexpression of HER2. In the future, it is necessary to conduct preclinical studies based on molecular subtyping to determine its optimal target population.
Looking ahead to the future, research directions for G7G4R should include: 1) further elucidating its interaction with gut microbiota and identifying the true effector molecules that exert activity in vivo after oral administration; 2) Develop new drug delivery systems, such as targeted delivery systems based on nanotechnology, to improve their tumor tissue enrichment and bioavailability; 3) Conduct systematic structure-activity relationship research, optimize its pharmacological and pharmacokinetic properties through glycosylation modification or semi synthetic modification; 4) Advance preclinical toxicology and pharmacology evaluations to lay the foundation for clinical trials.
Conclusion
Genistein 7-O - β - D-glucoside -4 '- O - [α - L-rhamnosyl - (1-2) - β - D-glucoside], as a natural isoflavone diglycoside with unique structure, has shown important research value in the field of breast cancer prevention and treatment by virtue of its multi target and multi-channel pharmacological action mechanism. It achieves comprehensive regulation of estrogen signaling, DNA repair, growth factor signaling, and cell cycle by regulating key targets such as ESR1, PGR, BRCA1, HER2, and CDK4. Although its physicochemical properties pose significant challenges for oral administration, this problem is expected to be solved through formulation innovation and structural optimization. In the future, with the deepening of research on natural product precise pharmacology and drug delivery system, G7G4R is expected to move from laboratory to clinical, providing a safe and effective natural drug choice for breast cancer patients, especially high-risk groups and patients with specific molecular subtypes. The systematic study of such complex glycosides not only helps to explore the modern scientific connotations of traditional Chinese medicine, but also provides valuable molecular templates for the development of innovative drugs based on natural products.
![Genistein 7-O-β-D-glucopyranoside-4’-O-[α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranoside]](/upload/0201/05/70404-42-1.png)
